USD 3.21
(-6.69%)
Breakdown | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|
Revenue | 1.47 Million | 2.92 Million | 2.09 Million | 1.06 Million |
Cost of Revenue | 753.91 Thousand | 1.63 Million | 305.16 Thousand | - |
Gross Profit | 723.91 Thousand | 1.29 Million | 1.78 Million | 1.06 Million |
Operating Expenses | 365.89 Million | 28.28 Million | 11.25 Million | 1.05 Million |
Selling, General and Administrative Expenses | 283.56 Million | 26.52 Million | 11.17 Million | 951.23 Thousand |
Research and Development Expenses | 90.97 Thousand | 92.54 Thousand | - | - |
Other Expenses | 82.24 Million | 235.5 Thousand | - | - |
Cost and Expenses | 366.65 Million | 28.28 Million | 11.25 Million | 1.05 Million |
Operating Income | -365.17 Million | -25.68 Million | -9.15 Million | -495.00 |
Interest Expense | 211.97 Thousand | 266.35 Thousand | 160.84 Thousand | 3910.00 |
Income Tax Expense | - | -1.4 Million | -14.82 Thousand | 961.00 |
Earnings before Tax | -364.66 Million | -25.49 Million | -9.14 Million | 8906.00 |
Net Income | -363.87 Million | -23.58 Million | -9.14 Million | 8906.00 |
Earnings Per Share Basic | -5.52 | -0.66 | -0.26 | 0.01 |
Earnings Per Share Diluted | -5.52 | -0.66 | -0.26 | 0.01 |
Weighted Average Shares Outstanding | 65.89 Million | 35.83 Million | 35.83 Million | 668.34 Thousand |
Weighted Average Shares Outstanding (Diluted) | 65.89 Million | 35.83 Million | 35.83 Million | 668.34 Thousand |
Gross Margin | 0.49 | 0.44 | 0.85 | 1.00 |
EBIT Margin | -246.02 | -8.40 | -4.35 | 0.06 |
Profit Margin | -246.22 | -8.06 | -4.37 | 0.01 |
EBITDA | -363.56 Million | -23.71 Million | -17.87 Million | 57.81 Thousand |
Earnings Before Tax Margin | -247.10 | -8.77 | -4.38 | -0.00 |
Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
---|---|---|---|---|---|---|
Revenue | 8261.00 | 41.38 Thousand | 1.47 Million | 414.8 Thousand | 556.27 Thousand | 11.06 Thousand |
Cost of Revenue | 1308.00 | 10.94 Thousand | 1.79 Million | 823.64 Thousand | 764.2 Thousand | -237.73 Thousand |
Gross Profit | 6953.00 | 30.44 Thousand | -318.04 Thousand | -408.83 Thousand | -207.93 Thousand | 248.79 Thousand |
Operating Expenses | 5.49 Million | 4.06 Million | 287.81 Million | 4.39 Million | 270.22 Million | 5.78 Million |
Selling, General and Administrative Expenses | 5.49 Million | 3.58 Million | - | 4.38 Million | 270.22 Million | 5.67 Million |
Research and Development Expenses | - | - | - | 9878.00 | 32.05 Thousand | 49.04 Thousand |
Other Expenses | -107.26 Thousand | - | 156.04 Thousand | - | - | - |
Cost and Expenses | 5.49 Million | 4.07 Million | 289.61 Million | 5.21 Million | 270.98 Million | 5.78 Million |
Operating Income | -5.48 Million | -4.2 Million | -288.13 Million | -4.8 Million | -347.51 Million | -5.76 Million |
Interest Expense | 2.26 Million | 96.14 Thousand | 211.97 Thousand | 61.33 Thousand | 58.97 Thousand | 43.67 Thousand |
Income Tax Expense | -346.26 Thousand | 96.14 Thousand | -788.82 Thousand | 185.95 Thousand | 1.32 Million | -1.25 Million |
Earnings before Tax | -7.09 Million | -3.84 Million | -364.66 Million | -4.53 Million | -347.48 Million | -5.66 Million |
Net Income | -6.75 Million | -3.84 Million | -363.87 Million | -4.72 Million | -348.74 Million | -4.36 Million |
Earnings Per Share Basic | -0.09 | -0.05 | - | -0.06 | -4.53 | -7.04 |
Earnings Per Share Diluted | -0.09 | -0.03 | - | -0.06 | -4.53 | -7.04 |
Weighted Average Shares Outstanding | 78.27 Million | 76.89 Million | 65.89 Million | 78.26 Million | 77.04 Million | 620.18 Thousand |
Weighted Average Shares Outstanding (Diluted) | 78.27 Million | 119.45 Million | 65.89 Million | 78.26 Million | 77.04 Million | 620.29 Thousand |
Gross Margin | 0.84 | 0.74 | -0.22 | -0.99 | -0.37 | 22.49 |
EBIT Margin | -554.35 | -74.78 | - | -11.41 | -484.62 | -499.53 |
Profit Margin | -817.11 | -92.90 | -246.22 | -11.38 | -626.94 | -394.85 |
EBITDA | -4.57 Million | -3.09 Million | - | -4.73 Million | -269.57 Million | -5.52 Million |
Earnings Before Tax Margin | -663.83 | -101.62 | -194.97 | -11.58 | -624.72 | -521.10 |
CAG
NG
ADV
BIOG-B
LGI
GISS